Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

RPR's enoxaparin reduces risk of DVT following hip replacement

Aug. 9, 1996

Hemaseel HMN phase I results announced

Aug. 9, 1996

Antithrombotic/antiallergic TxA2 synthase inhibitors from Terumo

July 26, 1996

Pharmacia & Upjohn introduces new dosage strength for Fragmin

July 26, 1996

D-HG: DIC/thrombosis treatment

July 26, 1996

BASF reports thrombin inhibitors

July 26, 1996

The Immune Response Corporation and Bayer to codevelop hemophilia A gene therapy

July 19, 1996

AlphaNine SD cleared by FDA

July 19, 1996

C85: TxB2 production/phosphoinositide breakdown inhibitor

July 19, 1996

Terumo discloses fibrinogen (gpIIb/IIIa) antagonists

July 19, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...